The Utility of Micro-RNA

MicroRNAs have demonstrated roles in human development, where their expression can drive or maintain tissue phenotype. Correspondingly their aberrant expression is a significant driver of the pathophysiology of many chronic diseases including diabetes and cancer. miRNA's are recognised as being highly stable ex vivo and miRNA signatures can be obtained from samples with poor ribosome integrity number (RIN) values. When this is combined with their undisputed biological importance it makes miRNA’s attractive biomarker candidates for a wide range of applications.

The utility of miRNA provides a means to generate cost-effective, information-rich cell characterisation tools and biomarkers for use in the Bioprocessing, Cell and Stem Cell Therapy, and Drug Discovery and Development markets. Click to find out how our innovative miRNA products can help you

About Sistemic

Sistemic is a development-stage biomedical company focused on the analysis of the information content of microRNA and other non-coding RNAs for applications in the development of cell therapies and drug repositioning. Sistemic’s patented and proprietary technology platforms provide a novel way to apply the information content of miRNA’s to overcome key obstacles to creating clinically useful stem cell therapies.

Recent News

Sistemic announce significant progress of pluripotent stem cell contamination technology in derived cell therapy products

Release Date: October 4, 2017

Glasgow, SCOTLAND. Sistemic Ltd. is excited to announce significant progress with the development of a miRNA-based assay for assessment of pluripotent stem cell (PSC) contamination in derived cell therapy products. The development is being undertaken in conjunction with LGC, the UK National Measurement Laboratory and Designated Institute for chemical and bio-measurement.  

Sistemic announces world-first with publication on the potential for patient stratification using a cell-based therapy for refractory rheumatoid arthritis

Release Date: January 9, 2017

Sistemic Ltd. announced today the publication of its ground-breaking research, undertaken together with TiGenix, identifying a set of circulating miRNA biomarkers which could potentially be used, if further clinically validated, to stratify refractory rheumatoid arthritis patients, prior to treatment, into responders and non-responders to an allogenic cell-based therapy: